The main risk is a broken proof chain: better
108Q metrics may not become accepted systems, recurring capacity demand, or trusted workflow revenue before valuation, competition, and
dilution matter again. Rigetti has more real assets and more funding flexibility than many peers, but the equity still needs commercial validation more than another roadmap promise.